Introduction：Basic information about CAS 180288-69-1|Trastuzumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Trastuzumab |
|---|
| CAS Number | 180288-69-1 | Molecular Weight | 145531.50 |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | C6470H10012N1726O2013S42 | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | Trastuzumab |
|---|
| Synonym | More Synonyms |
|---|
Trastuzumab BiologicalActivity
| Description | Trastuzumab (PBS) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (PBS) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>JAK/STAT Signaling >>EGFRSignaling Pathways >>Protein Tyrosine Kinase/RTK >>EGFR |
|---|
| References | [1]. Sliwkowski MX, et al. Nonclinical studies addressing the mechanism of action of trastuzumab. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70. [2]. Hudis CA, et al. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med. 2007 Jul 5;357(1):39-51. [3]. Barok M, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007 Jul;6(7):2065-72. |
|---|
Chemical & Physical Properties
| Molecular Formula | C6470H10012N1726O2013S42 |
|---|
| Molecular Weight | 145531.50 |
|---|
Synonyms
